Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers
NCT02273401 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96
Last updated 2014-10-24
Summary
To investigate safety, tolerability, and pharmacokinetics of BI 11054
Conditions
- Healthy
Interventions
- DRUG
-
BI 11054 CL
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-01-31
- Primary Completion
- 2008-08-31
More Related Trials
-
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
NCT02263976 ·Status: COMPLETED ·Phase: PHASE1
-
BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function
NCT02172118 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers
NCT02259959 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
NCT01818024 ·Status: COMPLETED ·Phase: PHASE1
-
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
NCT02231359 ·Status: COMPLETED
-
Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers
NCT01309139 ·Status: COMPLETED ·Phase: PHASE1
-
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
NCT04059094 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153
NCT02517359 ·Status: TERMINATED ·Phase: PHASE1
-
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02175342 ·Status: COMPLETED ·Phase: PHASE2
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05599191 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment
NCT02172781 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients
NCT02172534 ·Status: COMPLETED ·Phase: PHASE1
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
NCT05628740 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
NCT02367313 ·Status: COMPLETED ·Phase: PHASE2
-
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00240435 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00292448 ·Status: COMPLETED ·Phase: PHASE2
-
Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02182635 ·Status: COMPLETED ·Phase: PHASE3
-
A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers
NCT02198313 ·Status: TERMINATED ·Phase: PHASE1
-
A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)
NCT05354453 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects
NCT06918366 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
NCT03573505 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
NCT04562155 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients
NCT02315144 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
NCT06193031 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
NCT01172821 ·Status: COMPLETED ·Phase: PHASE3